SEC Form 4 · accession 0000899243-16-023719
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred M Powell
Officer — See Remarks
Period of report
Jun 23, 2016
Accepted (ET)
Jun 27, 2016 · 9:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 23, 2016 | M | 56,875 | $1.32 | A | 88,333 | D | |
| Common Stock | Jun 23, 2016 | F | 2,491 | $30.15 | D | 85,842 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option, Right to BuyF1 | $1.32 | Jun 23, 2016 | M | 56,875 | D | — | Jan 27, 2026 | Common Stock | 56,875 | 0 | D |
Explanation of responses
- F1These options vested on March 14, 2016, the date the Issuer announced analysis of overall survival of Study 301, its Phase 3 clinical study.
Remarks
Vice President and Chief Financial Officer